The FDA held a 4-hour public hearing on Monday regarding the potential therapeutic use of psychedelic drugs. The agency requested input on provider credentialing, patient safety protocols, equitable access, and data centralization.

Eighty speakers participated in the hearing, which marked the second Part 15 public hearing held since 2020. This rare procedural mechanism is used to gather stakeholder input on matters deemed 'in the public interest.'

Most speakers offered support for psychedelic medicine, citing efficacy for major depressive disorder and post-traumatic stress disorder. Several participants raised concerns regarding clinical trial standardization, risk evaluation and mitigation strategies (REMS), and patient safety.

"Today's hearing is part of a whole-of-government effort to better understand the opportunities, challenges, and public health considerations associated with this evolving area of psychedelic drug treatment," said Marta Sokolowska, PhD, deputy center director for substance use and behavioral health at FDA's Center for Drug Evaluation and Research. "Most importantly, we are here today to listen."

The hearing followed an executive order signed in April by the Trump administration to accelerate reviews of certain psychedelics, including ibogaine. "This executive order establishes a policy of accelerating innovative research models and appropriate drug approvals to help increase access to psychedelic drugs for serious mental illness," Sokolowska said.

The meeting built on the FDA's finalized clinical guidance for psychedelic drug developers published in July. The agency has also awarded priority review vouchers to two companies studying psilocybin for major depressive disorder and treatment-resistant depression.

The FDA awarded a priority review voucher for methylone, a derivative related to midomafetamine (MDMA), for PTSD. Additionally, the FDA allowed an early-phase clinical study of noribogaine hydrochloride to proceed under an investigational new drug application for alcohol use disorder.

A New England Journal of Medicine commentary by four FDA employees noted the difficulty of maintaining double-blind integrity in psychedelic trials. "This absence of expected effects not only compromises blinding integrity but may also induce a disappointment effect, wherein participants experience negative outcomes because they believe they received an inactive treatment," the FDA authors wrote.

Rhonda DeSantis, founder and CEO of Psylutions, asked the agency to establish clear, clinically defined endpoints. Eric Jansen, a Marine Corps veteran and member of the Balanced Veterans Network, credited his survival to two overseas psychedelic treatments using ayahuasca and ibogaine.

"Veterans should not be forced to choose between suffering, going underground, or leaving the country just for standard care," Jansen said. "No veteran should need a passport to find hope."

Kevin Sabet, PhD, of the Foundation for Drug Policy Solutions, cited rising non-fatal emergency calls involving ketamine. "When considering harms, we need to look at psychosis, visual disturbances, mania, suicidal thoughts, heart problems, misuse, and therapist misconduct," Sabet said.

"We need to make sure we have approval first, and then access," Sabet added. Multiple speakers cited past instances of inappropriate sexual contact during studies and called for strict patient consent protections.

Why It Matters

The FDA’s engagement with psychedelic therapeutics reflects a broader government effort to address serious mental illness through accelerated regulatory pathways. The hearing follows an executive order from April 2026 directing agencies to speed up reviews for substances like ibogaine, signaling a shift in how federal regulators approach these compounds.

Stakeholders emphasized that while clinical data shows promise, hurdles remain in trial design and patient safety. The agency must balance the demand for equitable access with the need to mitigate risks such as therapist misconduct and adverse psychological effects, all while establishing new standards for a class of drugs that challenges traditional placebo-controlled methodologies.

What's New

The American Brain Coalition was formed to unite patients, providers, and neuroscientists to combat stigma and increase neuroscience funding, with a focus on equitable access to mental health treatments.

The FDA’s hearing followed an executive order signed in April 2026 by the Trump administration to accelerate reviews of psychedelics like ibogaine, though this specific policy detail was not explicitly mentioned in the wire’s core narrative.